25 LLC’s Summit Therapeutics SMMT Stock Holding History

25 LLC’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-200	Closed	-$440	–	474
2023 Q2	$440	Hold	200	–	–	﹤0.01%	588
2023 Q1	$388	Buy	+200	New	+$545	﹤0.01%	484

Other funds holding SMMT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

25 LLC's SMMT Position: Q3 2023 in Review

25 LLC sold out of Summit Therapeutics (SMMT) in Q3 2023, closing a stake of 200 shares — an estimated $440 sold.

25 LLC first reported a position in SMMT in Q1 2023 and held it in 2 quarters. The position peaked at $440 in Q2 2023. 93 funds tracked by Wall St. Rank hold SMMT as of Q3 2023.

25 LLC reported no remaining Summit Therapeutics position as of Q3 2023 after selling out during the quarter.
25 LLC sold 200 Summit Therapeutics shares in Q3 2023, an estimated $440.
25 LLC first reported a position in Summit Therapeutics in Q1 2023 and held it in 2 quarters.
25 LLC's Summit Therapeutics position peaked at $440 in Q2 2023.
93 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.